635 related articles for article (PubMed ID: 31366777)
1. Role of Advanced Glycation Endproduct (AGE)-Receptor for Advanced Glycation Endproduct (RAGE) Axis in Cardiovascular Disease and Its Therapeutic Intervention.
Yamagishi SI
Circ J; 2019 Aug; 83(9):1822-1828. PubMed ID: 31366777
[TBL] [Abstract][Full Text] [Related]
2. DNA-aptamers raised against AGEs as a blocker of various aging-related disorders.
Yamagishi S; Taguchi K; Fukami K
Glycoconj J; 2016 Aug; 33(4):683-90. PubMed ID: 27338620
[TBL] [Abstract][Full Text] [Related]
3. Glycation and cardiovascular disease in diabetes: A perspective on the concept of metabolic memory.
Yamagishi SI; Nakamura N; Matsui T
J Diabetes; 2017 Feb; 9(2):141-148. PubMed ID: 27556881
[TBL] [Abstract][Full Text] [Related]
4. Phytochemicals Against Advanced Glycation End Products (AGEs) and the Receptor System.
Yamagishi SI; Matsui T; Ishibashi Y; Isami F; Abe Y; Sakaguchi T; Higashimoto Y
Curr Pharm Des; 2017; 23(8):1135-1141. PubMed ID: 27774900
[TBL] [Abstract][Full Text] [Related]
5. Relationship of Advanced Glycation End Products With Cardiovascular Disease in Menopausal Women.
Pertynska-Marczewska M; Merhi Z
Reprod Sci; 2015 Jul; 22(7):774-82. PubMed ID: 25228634
[TBL] [Abstract][Full Text] [Related]
6. Advanced Glycation End Products: A Molecular Target for Vascular Complications in Diabetes.
Yamagishi S; Nakamura N; Suematsu M; Kaseda K; Matsui T
Mol Med; 2015 Oct; 21 Suppl 1(Suppl 1):S32-40. PubMed ID: 26605646
[TBL] [Abstract][Full Text] [Related]
7. Blockade of the advanced glycation end products (AGEs) and their receptor (RAGE) system is a possible mechanism for sustained beneficial effects of multifactorial intervention on mortality in type 2 diabetes.
Yamagishi S; Matsui T; Nakamura K
Med Hypotheses; 2008 Nov; 71(5):749-51. PubMed ID: 18710793
[TBL] [Abstract][Full Text] [Related]
8. Role of advanced glycation end products (AGEs) and oxidative stress in diabetic retinopathy.
Yamagishi S; Ueda S; Matsui T; Nakamura K; Okuda S
Curr Pharm Des; 2008; 14(10):962-8. PubMed ID: 18473846
[TBL] [Abstract][Full Text] [Related]
9. Advanced Glycation End Products and Their Involvement in Cardiovascular Disease.
Yubero-Serrano EM; Pérez-Martínez P
Angiology; 2020 Sep; 71(8):698-700. PubMed ID: 32242451
[No Abstract] [Full Text] [Related]
10. Therapeutic Interventions for Advanced Glycation-End Products and its Receptor- Mediated Cardiovascular Disease.
Prasad K; Tiwari S
Curr Pharm Des; 2017; 23(6):937-943. PubMed ID: 27719648
[TBL] [Abstract][Full Text] [Related]
11. DNA aptamer raised against receptor for advanced glycation end products suppresses renal tubular damage and improves insulin resistance in diabetic mice.
Sotokawauchi A; Matsui T; Higashimoto Y; Nishino Y; Koga Y; Yagi M; Yamagishi SI
Diab Vasc Dis Res; 2021; 18(1):1479164121990533. PubMed ID: 33535822
[TBL] [Abstract][Full Text] [Related]
12. Advanced glycation end products (AGEs) and cardiovascular disease (CVD) in diabetes.
Yamagishi S; Matsui T; Ueda S; Nakamura K; Imaizumi T
Cardiovasc Hematol Agents Med Chem; 2007 Jul; 5(3):236-40. PubMed ID: 17630950
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic Potential of DNA-aptamers Raised Against AGE-RAGE Axis in Diabetes-related Complications.
Yamagishi SI; Matsui T
Curr Pharm Des; 2018; 24(24):2802-2809. PubMed ID: 30156152
[TBL] [Abstract][Full Text] [Related]
14. Implication of advanced glycation end products (Ages) and their receptor (Rage) on myocardial contractile and mitochondrial functions.
Neviere R; Yu Y; Wang L; Tessier F; Boulanger E
Glycoconj J; 2016 Aug; 33(4):607-17. PubMed ID: 27277623
[TBL] [Abstract][Full Text] [Related]
15. AGE-RAGE axis blockade in diabetic nephropathy: Current status and future directions.
Sanajou D; Ghorbani Haghjo A; Argani H; Aslani S
Eur J Pharmacol; 2018 Aug; 833():158-164. PubMed ID: 29883668
[TBL] [Abstract][Full Text] [Related]
16. Advanced Glycation End Products: Potential Mechanism and Therapeutic Target in Cardiovascular Complications under Diabetes.
Yang P; Feng J; Peng Q; Liu X; Fan Z
Oxid Med Cell Longev; 2019; 2019():9570616. PubMed ID: 31885827
[TBL] [Abstract][Full Text] [Related]
17. Kinetics, role and therapeutic implications of endogenous soluble form of receptor for advanced glycation end products (sRAGE) in diabetes.
Yamagishi S; Matsui T; Nakamura K
Curr Drug Targets; 2007 Oct; 8(10):1138-43. PubMed ID: 17979674
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular disease: what's all the AGE/RAGE about?
Barlovic DP; Thomas MC; Jandeleit-Dahm K
Cardiovasc Hematol Disord Drug Targets; 2010 Mar; 10(1):7-15. PubMed ID: 20041839
[TBL] [Abstract][Full Text] [Related]
19. Smooth muscle cell pathophysiology and advanced glycation end products (AGEs).
Yamagishi S; Matsui T
Curr Drug Targets; 2010 Jul; 11(7):875-81. PubMed ID: 20412043
[TBL] [Abstract][Full Text] [Related]
20. Advanced Glycation End Products, Diabetes, and Bone Strength.
Yamamoto M; Sugimoto T
Curr Osteoporos Rep; 2016 Dec; 14(6):320-326. PubMed ID: 27704396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
